Intismeran autogene clinical trials
Also written mRNA-4157.
How each study uses intismeran autogene is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the intismeran autogene studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2024 (4)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 1 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 0
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test intismeran autogene.
- Apr 2027A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)Phase 1/2 · Merck Sharp & Dohme LLC
- Nov 2027Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid TumorsPhase 1 · ModernaTX, Inc.
Studies
Open first, then newest update. How each study uses intismeran autogene is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07513376Written as Intismeran
- A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)RecruitingPhase 2Merck Sharp & Dohme LLCNCT07221474Written as Intismeran Autogene
- A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06623422Written as Intismeran autogene
- A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)RecruitingPhase 2Merck Sharp & Dohme LLCNCT06833073Written as Intismeran autogene
- A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)Active, not recruitingPhase 2Merck Sharp & Dohme LLCNCT06961006Written as Intismeran autogene
- A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT06077760Written as Intismeran autogene
- An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)Active, not recruitingPhase 2ModernaTX, Inc.NCT03897881Written as mRNA-4157
- Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid TumorsActive, not recruitingPhase 1ModernaTX, Inc.NCT03313778Written as mRNA-4157
- A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).Active, not recruitingPhase 2Merck Sharp & Dohme LLCNCT06307431Written as Intismeran autogene
- A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)TerminatedPhase 2/3Merck Sharp & Dohme LLCNCT06295809Written as Intismeran autogene
- A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)Active, not recruitingPhase 1/2Merck Sharp & Dohme LLCNCT06305767Written as Intismeran autogene
- A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT05933577Written as Intismeran autogene
Codes
What other systems call intismeran autogene · ClinicalTrials.gg INT018685
- UNII (FDA) ZG6U44T8SGINTISMERAN AUTOGENEOne source FDA
- NCI Thesaurus C146813Intismeran AutogeneOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | ZG6U44T8SG | INTISMERAN AUTOGENE | One source FDA |
| NCI Thesaurus | C146813 | Intismeran Autogene | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.